ATE234862T1 - Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen - Google Patents

Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen

Info

Publication number
ATE234862T1
ATE234862T1 AT99925135T AT99925135T ATE234862T1 AT E234862 T1 ATE234862 T1 AT E234862T1 AT 99925135 T AT99925135 T AT 99925135T AT 99925135 T AT99925135 T AT 99925135T AT E234862 T1 ATE234862 T1 AT E234862T1
Authority
AT
Austria
Prior art keywords
disclosed
glycoproteins
pharmaceutical compositions
properties
therapeutic uses
Prior art date
Application number
AT99925135T
Other languages
English (en)
Inventor
Michael John Tisdale
Penio Todorov Todorov
Original Assignee
Michael John Tisdale
Penio Todorov Todorov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael John Tisdale, Penio Todorov Todorov filed Critical Michael John Tisdale
Application granted granted Critical
Publication of ATE234862T1 publication Critical patent/ATE234862T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99925135T 1998-05-29 1999-06-01 Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen ATE234862T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811465.5A GB9811465D0 (en) 1998-05-29 1998-05-29 Glycoproteins having lipid mobilising properties and therapeutic applications thereof
PCT/GB1999/001509 WO1999062939A2 (en) 1998-05-29 1999-06-01 Glycoproteins having lipid mobilising properties and therapeutic applications thereof

Publications (1)

Publication Number Publication Date
ATE234862T1 true ATE234862T1 (de) 2003-04-15

Family

ID=10832846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99925135T ATE234862T1 (de) 1998-05-29 1999-06-01 Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen

Country Status (10)

Country Link
US (6) US6890899B1 (de)
EP (1) EP1082344B1 (de)
JP (2) JP2002519303A (de)
AT (1) ATE234862T1 (de)
AU (1) AU4152799A (de)
CA (1) CA2329138C (de)
DE (1) DE69906064T2 (de)
ES (1) ES2194464T3 (de)
GB (1) GB9811465D0 (de)
WO (1) WO1999062939A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60224064T2 (de) * 2001-10-05 2008-11-20 Serono Genetics Institute S.A. Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit
CA2462588A1 (en) * 2001-10-12 2003-04-24 Genset S.A. Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
EP1548445A3 (de) * 2003-12-22 2005-11-23 F. Hoffmann-La Roche Ag Neue Ziele im Fettgewebe zur Fettleibigkeit
WO2007057119A2 (en) * 2005-11-15 2007-05-24 F. Hoffmann-La Roche Ag AZGP GENE SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs)
WO2007066484A1 (ja) * 2005-12-08 2007-06-14 Sapporo Breweries Limited ストレス判定方法、ストレス判定用マーカー、ストレス判定用診断薬及びストレス判断システム
EP2318021A4 (de) * 2008-06-26 2012-10-31 Healthlinx Ltd Protokolle zur behandlung und prävention von fettsucht und daraus entstehenden komplikationen
US20100173829A1 (en) 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
DK3459558T3 (da) 2010-06-25 2020-11-02 Univ Aston Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
CN103458983A (zh) * 2011-02-10 2013-12-18 莱顿大学医学中心 通过使用含棉的固定相的色谱法纯化聚糖和/或糖缀合物的方法
EP2879690A1 (de) * 2012-07-31 2015-06-10 Aston University Gezielte ösophageale verabreichung von zn-alpha2-glycoproteinen (zag), verfahren und formulierungen daraus
EP3077823B1 (de) 2013-12-05 2019-09-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zur identifikation und behandlung von kachexie oder prä-kachexie
EP3389715A4 (de) 2015-12-14 2019-06-12 David K. Thomas Zusammensetzungen und verfahren zur behandlung von kardialer dysfunktion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip

Also Published As

Publication number Publication date
CA2329138C (en) 2010-12-21
US20160046704A1 (en) 2016-02-18
US6890899B1 (en) 2005-05-10
US20060160723A1 (en) 2006-07-20
DE69906064D1 (de) 2003-04-24
US20100151589A1 (en) 2010-06-17
CA2329138A1 (en) 1999-12-09
GB9811465D0 (en) 1998-07-29
EP1082344B1 (de) 2003-03-19
US20150183843A1 (en) 2015-07-02
US7550429B2 (en) 2009-06-23
DE69906064T2 (de) 2004-03-04
ES2194464T3 (es) 2003-11-16
US20140242089A1 (en) 2014-08-28
EP1082344A2 (de) 2001-03-14
WO1999062939A2 (en) 1999-12-09
AU4152799A (en) 1999-12-20
WO1999062939A3 (en) 2000-03-16
JP2002519303A (ja) 2002-07-02
JP2013177395A (ja) 2013-09-09

Similar Documents

Publication Publication Date Title
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BR9814615A (pt) Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
EP1100535A4 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
ATE234862T1 (de) Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen
ATE337019T1 (de) Geladene lipide und deren verwendung
ATE213292T1 (de) Lotion enthaltendes tissuepapier das einen flüssigen polyolpolyesterweichmacher und ein immobilisierendes mittel enthält
ATE240395T1 (de) Antikörper gegen e-selektin
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
BR0206985A (pt) Anticorpos modificados e métodos de uso
ID29158A (id) Monoester probukol untuk pengobatan penyakit kardiovaskular dan peradangan
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
ATE232396T1 (de) Oxydiertes thymosin beta 4
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082344

Country of ref document: EP

EEIH Change in the person of patent owner